Platinum Coordination Derivatives by the Intraperitoneal Route: Pharmacokinetics and Clinical Results
Notwithstanding improvement of treatment results in ovarian cancer, even the patient who achieved a complete remission may face a relapse. The seven year follow-up figures of the study performed in the Netherlands (1), which compared cisplatin containing combination chemotherapy CHAP-5 (cyclophosphamide, hexamethylmelamine, adriamy-cin and cisplatin) with HexaCAF (hexamethylmelamine, cyclophosphamide, adriamycin and 5-flourouracil) show a steadily decrease of the number of disease free patients upto 60–70% of those formerly in complete remission. Therefore even for patients in complete remission as a result of cisplatin based combination chemotherapy new treatment strategies seem warranted. For the other, not reaching a complete remission this counts the more. Late intensification by an increased dose of cisplatin for instance could offer such a new treatment avenue, based on the theory of Goldie and Coldman (2). Such an increased dose might overcome acquired cisplatin resistance of remaining tumorcells.
KeywordsOvarian Cancer Complete Remission Minimal Residual Disease Intraperitoneal Chemotherapy Disease Free Patient
Unable to display preview. Download preview PDF.
- 1.Neijt, J.P., Ten Bokkel Huinink, W.W., Van der Burg, M.E.L., et al. Randomised trial comparing two combination chemotherapy regimens (HexaCAF vs CHAP-5) in advanced ovarian carcinoma. The Lancet: 594–600, 1984.Google Scholar
- 5.Ten Bokkel Huinink, W.W., Van der Burg, M.E.L., Van Oosterom, A.T., Dalesio, O., Rotmensz, N., Vermorken, J.B. Carboplatin replacing cisplatin in combination chemotherapy for ovarian cancer. A large scale randomized phase III trial of the Gynecological Cancer Cooperative Group of EORTC. ASCO abstract for the annual meeting, May, 1987.Google Scholar